Advanced

Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes

Cunha, Joao P M C M LU ; Gysemans, Conny; Gillard, Pieter and Mathieu, Chantal (2018) In Current Diabetes Reviews 14(1). p.3-13
Abstract

INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of... (More)

INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of immunosuppressive drugs as well as oxidative stress caused by hypoxia or inflammation. On the other hand, the islet transplant procedure provides the possibility to undertake multiple practical and beneficial manipulations of the beta cells before engraftment with the intention to reach improved graft survival results.

CONCLUSION: We have focused on the current status of various obstacles in islet transplantation and on the potential of (stem)cell-based treatments able to stimulate islet graft outcome in pre-clinical and clinical transplantation settings in which specific attention is given to the engraftment-enhancing and immunomodulatory potential of various types of stem cells..

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Animals, Diabetes Mellitus, Type 1/immunology, Graft Survival, Humans, Islets of Langerhans Transplantation/adverse effects, Stem Cell Transplantation/adverse effects, Transplantation Immunology, Treatment Outcome
in
Current Diabetes Reviews
volume
14
issue
1
pages
3 - 13
publisher
Bentham Science Publishers
external identifiers
  • scopus:85042348350
ISSN
1573-3998
DOI
10.2174/1573399812666160629094031
language
English
LU publication?
no
id
a3ae3dac-0a24-4c50-af18-7e38692172b7
date added to LUP
2019-02-14 09:43:55
date last changed
2019-10-15 06:58:41
@article{a3ae3dac-0a24-4c50-af18-7e38692172b7,
  abstract     = {<p>INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of immunosuppressive drugs as well as oxidative stress caused by hypoxia or inflammation. On the other hand, the islet transplant procedure provides the possibility to undertake multiple practical and beneficial manipulations of the beta cells before engraftment with the intention to reach improved graft survival results.</p><p>CONCLUSION: We have focused on the current status of various obstacles in islet transplantation and on the potential of (stem)cell-based treatments able to stimulate islet graft outcome in pre-clinical and clinical transplantation settings in which specific attention is given to the engraftment-enhancing and immunomodulatory potential of various types of stem cells..</p>},
  author       = {Cunha, Joao P M C M and Gysemans, Conny and Gillard, Pieter and Mathieu, Chantal},
  issn         = {1573-3998},
  keyword      = {Animals,Diabetes Mellitus, Type 1/immunology,Graft Survival,Humans,Islets of Langerhans Transplantation/adverse effects,Stem Cell Transplantation/adverse effects,Transplantation Immunology,Treatment Outcome},
  language     = {eng},
  number       = {1},
  pages        = {3--13},
  publisher    = {Bentham Science Publishers},
  series       = {Current Diabetes Reviews},
  title        = {Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes},
  url          = {http://dx.doi.org/10.2174/1573399812666160629094031},
  volume       = {14},
  year         = {2018},
}